- Home
- SGMO vs NTHI Comparison
SGMO vs NTHI Comparison
Compare SGMO & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- NTHI
- Stock Information
- Founded
- SGMO 1995
- NTHI 2008
- Country
- SGMO United States
- NTHI United States
- Employees
- SGMO N/A
- NTHI N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- SGMO Health Care
- NTHI Health Care
- Exchange
- SGMO Nasdaq
- NTHI Nasdaq
- Market Cap
- SGMO 122.8M
- NTHI 142.5M
- IPO Year
- SGMO 2000
- NTHI N/A
- Fundamental
- Price
- SGMO $0.46
- NTHI $4.26
- Analyst Decision
- SGMO Buy
- NTHI
- Analyst Count
- SGMO 6
- NTHI 0
- Target Price
- SGMO $4.50
- NTHI N/A
- AVG Volume (30 Days)
- SGMO 4.1M
- NTHI 24.1K
- Earning Date
- SGMO 08-05-2025
- NTHI 01-01-0001
- Dividend Yield
- SGMO N/A
- NTHI N/A
- EPS Growth
- SGMO N/A
- NTHI N/A
- EPS
- SGMO N/A
- NTHI N/A
- Revenue
- SGMO $63,756,000.00
- NTHI $79,990.00
- Revenue This Year
- SGMO N/A
- NTHI N/A
- Revenue Next Year
- SGMO N/A
- NTHI N/A
- P/E Ratio
- SGMO N/A
- NTHI N/A
- Revenue Growth
- SGMO 239.92
- NTHI 13.52
- 52 Week Low
- SGMO $0.30
- NTHI $4.11
- 52 Week High
- SGMO $3.18
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- SGMO 38.27
- NTHI N/A
- Support Level
- SGMO $0.49
- NTHI N/A
- Resistance Level
- SGMO $0.51
- NTHI N/A
- Average True Range (ATR)
- SGMO 0.04
- NTHI 0.00
- MACD
- SGMO 0.01
- NTHI 0.00
- Stochastic Oscillator
- SGMO 6.25
- NTHI 0.00
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").